Structures by: Eddleston M. D.
Total: 25
C12H8N2,C5H6O4
C12H8N2,C5H6O4
CrystEngComm (2013) 15, 1 175
a=16.5230(1)Å b=15.9952(3)Å c=5.4792(3)Å
α=90.00° β=90.00° γ=90.00°
C12H8N2,C5H6O4,H2O
C12H8N2,C5H6O4,H2O
CrystEngComm (2013) 15, 1 175
a=27.495(2)Å b=14.043(2)Å c=4.0898(4)Å
α=90.00° β=90.00° γ=90.00°
Caffeine:Theophylline cocrystal
C8H10N4O2,C7H8N4O2
Chem.Commun. (2012) 48, 8075
a=7.0081(7)Å b=8.7904(7)Å c=13.0856(15)Å
α=95.648(8)° β=97.090(9)° γ=91.667(8)°
Caffeine:anthranilic acid co-crystal
C8H10N4O2,C7H7NO2
Acta Crystallographica Section B (2014) 70, 1 72-80
a=14.53798(14)Å b=11.07930(8)Å c=10.02456(7)Å
α=90° β=90° γ=90°
Caffeine:anthranilic acid co-crystal
C8H10N4O2,C7H7NO2
Acta Crystallographica Section B (2014) 70, 1 72-80
a=8.4853(2)Å b=13.4240(3)Å c=14.8856(4)Å
α=111.7249(16)° β=92.8464(15)° γ=93.5278(9)°
Caffeine:anthranilic acid hemichlorobenzene
2(C8H10N4O2),2(C7H7NO2),C6H5Cl
Acta Crystallographica Section B (2014) 70, 1 72-80
a=12.4390(2)Å b=13.1409(2)Å c=13.2251(3)Å
α=69.439(1)° β=80.418(1)° γ=63.557(1)°
Caffeine:anthranilic acid hemitoluene
2(C8H10N4O2),2(C7H7NO2),C7H8
Acta Crystallographica Section B (2014) 70, 1 72-80
a=12.475(9)Å b=13.488(9)Å c=13.316(9)Å
α=68.318(11)° β=79.948(16)° γ=64.124(11)°
Caffeine:anthranilic acid hemibromobenzene
2(C8H10N4O2),2(C7H7NO2),C6H5Br
Acta Crystallographica Section B (2014) 70, 1 72-80
a=12.569(3)Å b=13.409(3)Å c=13.269(3)Å
α=68.991(4)° β=80.215(5)° γ=64.007(4)°
Caffeine:anthranilic acid mono o-xylene
C8H10N4O2,C7H7NO2,C8H10
Acta Crystallographica Section B (2014) 70, 1 72-80
a=13.8492(3)Å b=6.7890(2)Å c=23.3960(7)Å
α=90.00° β=92.260(1)° γ=90.00°
Caffeine:anthranilic acid mono toluene
C8H10N4O2,C7H7NO2,C7H8
Acta Crystallographica Section B (2014) 70, 1 72-80
a=6.7113(3)Å b=13.5803(6)Å c=23.579(2)Å
α=87.100(2)° β=88.572(2)° γ=86.065(2)°
Theobromine:anthranilic acid co-crystal
C7H8N4O2,C7H7NO2
Acta Crystallographica Section B (2014) 70, 1 72-80
a=6.5769(10)Å b=21.905(3)Å c=11.0496(16)Å
α=90° β=112.912(6)° γ=90°
Caffeine:anthranilic acid sesqui p-xylene
C8H10N4O2,C7H7NO2,1.5(C8H10)
Acta Crystallographica Section B (2014) 70, 1 72-80
a=6.8474(8)Å b=13.431(2)Å c=14.440(3)Å
α=77.009(3)° β=86.596(4)° γ=88.687(8)°
Caffeine:anthranilic acid monohydrate
C8H10N4O2,C7H7NO2,H2O
Acta Crystallographica Section B (2014) 70, 1 72-80
a=10.2641(2)Å b=26.9469(7)Å c=11.9845(3)Å
α=90.00° β=103.547(2)° γ=90.00°
Carbamazepine-trifluoroacetic acid (1/1)
C15H12N2O1,C2H1F3O2
Acta Crystallographica Section C (2013) 69, 11 1260-1266
a=14.9968(12)Å b=5.2660(3)Å c=20.1911(12)Å
α=90.00° β=102.191(7)° γ=90.00°
Carbamazepine--trifluoroacetic acid (1/1)
C15H12N2O1,C2H1F3O2
Acta Crystallographica Section C (2013) 69, 11 1260-1266
a=14.9970(3)Å b=5.37120(10)Å c=20.4441(4)Å
α=90.00° β=101.529(2)° γ=90.00°
Carbamazepine mesylate
C15H13N2O1,C1H3O3S1
Acta Crystallographica Section C (2013) 69, 11 1260-1266
a=5.5673(7)Å b=15.7196(19)Å c=18.125(2)Å
α=90.00° β=97.641(4)° γ=90.00°
9,10-Dihydrocarbamazepine mesylate
C15H15N2O1,C1H3O3S1
Acta Crystallographica Section C (2013) 69, 11 1260-1266
a=5.4477(2)Å b=15.7340(7)Å c=18.5034(8)Å
α=90.00° β=96.647(4)° γ=90.00°
1:1 theophylline benzamide cocrystal Form I
C7H8N4O2,C7H7NO
Crystal Growth & Design (2015)
a=7.5275(2)Å b=13.3891(4)Å c=13.8564(4)Å
α=90.00° β=91.486(2)° γ=90.00°
1:1 theophylline acetamide cocrystal
C7H8N4O2,C2H5NO
Crystal Growth & Design (2015)
a=7.6545(13)Å b=8.3489(14)Å c=8.9540(16)Å
α=90.552(8)° β=91.339(11)° γ=110.177(12)°
1:1 theophylline N,N-dimethylformamide cocrystal
C7H8N4O2,C3H7NO
Crystal Growth & Design (2015)
a=4.4183(1)Å b=14.3872(6)Å c=19.3622(9)Å
α=90.00° β=93.41(3)° γ=90.00°
1:1 theophylline formamide cocrystal Form I
C7H8N4O2,CH3NO
Crystal Growth & Design (2015)
a=8.7314(3)Å b=6.6582(3)Å c=8.8996(4)Å
α=90.00° β=98.546(2)° γ=90.00°
1:1 theophylline formamide cocrystal Form II
C7H8N4O2,CH3NO
Crystal Growth & Design (2015)
a=6.6058(13)Å b=8.7163(17)Å c=8.8843(18)Å
α=81.34(3)° β=87.63(3)° γ=87.47(3)°
1:1 theophylline N-methylformamide cocrystal
C7H8N4O2,C2H5NO
Crystal Growth & Design (2015)
a=6.6316(3)Å b=8.7905(4)Å c=9.5955(4)Å
α=92.441(2)° β=92.929(2)° γ=90.609(2)°
1:1 theophylline pyrazinamide cocrystal Form II
C7H8N4O2,C5H5N3O
Crystal Growth & Design (2015)
a=7.4800(2)Å b=7.6959(2)Å c=12.7028(4)Å
α=86.113(2)° β=75.930(2)° γ=68.995(2)°
1:1 theophylline pyrazinamide cocrystal Form I
(C7H8N4O2),(C5H5N3O1)
Crystal Growth & Design (2015)
a=13.4545(15)Å b=13.2880(19)Å c=7.62149(40)Å
α=90° β=90° γ=90°